Abstract
SARS-CoV-2 and Mycobacterium tuberculosis (Mtb) share similarities in their modes of transmission, pathophysiological symptoms, and manifestations. An imbalance in the immune response characterized by significantly elevated levels of some inflammatory cytokines may increase the risk of developing both tuberculosis (TB) and COVID-19 as a comorbid condition. The role of SNPs in ace2 and tmprss2 conferring higher susceptibility to TB-COVID-19 co-infection is relatively underexplored. In this study, a Cameroonian cohort consisting of COVID-19-infected (n = 31), TB-infected (n = 43), TB-COVID-19 co-infected (n = 21), and a control group (n = 24) was studied. The immune response and disease severity were estimated by quantitating inflammatory cytokine levels and self-reported and clinically diagnosed symptoms. We identified SNPs in ace2 and tmprss2 genes previously associated with COVID-19 susceptibility and assessed their association with comorbid conditions. We identified genotypes (Allele AG: rs147311723, rs35803318; Allele AA: rs2074192; Allele CG: rs4240157; Allele AG: rs4646179) in ace2 gene and (Allele CA: rs61735791, Allele CT: rs12329760) in tmprss2 genes that are putatively associated with higher susceptibility to both TB and COVID-19. This study underscores the significant genetic and immunological factors contributing to susceptibility to TB and COVID-19 co-infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the African coaLition for Epidemic Research, Response and Training (ALERRT) which is part of the EDCTP2 Programme supported by the European Union under grant agreement RIA2016E-1612. ALERRT is also supported by the United Kingdom National Institute for Health Research and the Wellcome Trust (Ref 221012/Z/20/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was obtained from the Cameroon National Ethical Committee for Research in Human Health (No 2020/07/1265/CE/CNERSH/SP) in Yaounde.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
